MORE►
AyuVis
Photo: UNT System
UNT Health, TechFW Renew Partnership to Drive Regional Health Innovation
by Sandra Engelland | Jan 14, 2026
Backed by funding from the Texas Legislature, the collaboration aims to connect researchers, entrepreneurs, and investors to speed the development of new technologies that can move out of the lab and into real world applications.
by David Seeley |
Aug 23, 2024
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
MORE►
by Lance Murray |
May 17, 2023
The grant from the National Heart, Lung, and Blood Institute will fund a first-in-human Phase 1 clinical trial of a new generation of immunotherapies. This is the fourth NIH grant AyuVis has received since its founding in 2014, doubling total non-dilutive funding to $4.2 million. Co-Founder and CEO Dr. Suchismita Acharya calls the move to a human trial "a huge milestone for AyuVis."
MORE►
by Kevin Cummings |
May 17, 2022
What companies are finding funding or having a big exit? From startup investments to grants and acquisitions, Dallas Innovates tracks what’s happening in North Texas money.
MORE►
[Image: chaunpis/istockphoto]
Fort Worth’s AyuVis Is One Step Closer to Protecting Pre-Term Babies from a Leading Cause of Death
by David Kirkpatrick | Mar 31, 2022
Fort Worth-based AyuVis just received its second patent in three months for its immunotherapy treatments that protect pre-term babies from a debilitating chronic lung disease that affects many pre-term infants on ventilators.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
MORE►
